SYM 2206 (a potent non-competitive AMPA receptor antagonist) elevates the threshold for maximal electroshock-induced seizures in mice
PDF

Keywords

threshold for maximal electroshock-induced seizures
mice.
SYM 2206
TID20
TID50

Abstract

The aim of this study was to determine the effect of SYM 2206 (a potent non-competitive AMPA receptor antagonist) on the threshold for maximal electroshock (MEST)-induced seizures in mice. Electroconvulsions were produced in mice by means of a current (sinewave, 50 Hz, maximum 500 V, strength from 4 to 14 mA, 0.2-s stimulus duration, tonic hind limb extension taken as the endpoint) delivered via ear-clip electrodes. SYM 2206 administered systemically (i.p.), 30 min before the MEST test, at doses of 2.5 and 5 mg/kg, did not alter the threshold for maximal electroconvulsions in mice. In contrast, SYM 2206 at doses of 10 and 20 mg/kg significantly elevated the threshold for maximal electroconvulsions in mice (P<0.01 and P<0.001). Linear regression analysis of SYM 2206 doses and their corresponding threshold increases allowed for the determination of threshold increasing doses by 20% and 50% (TID20and TID50values) that elevate the threshold in drug-treated animals over the threshold in control animals. The experimentally derived TID20and TID50values for SYM 2206 were 4.25 and 10.56 mg/kg, respectively. SYM 2206 dose-dependently increased the threshold for MEST-induced seizures, suggesting the anticonvulsant action of the compound in this seizure model in mice.

PDF

References

1. Behr J. et al.: Kindling enhances kainite receptor-mediated depression of GABAergic inhibition in rat granule cells. Eur. J. Neurosci., 16, 861, 2002.

2. Ghersi C. et al.: Pharmacological heterogeneity of release-regulating presynaptic AMPA/kainate receptors in the rat brain: study with receptor antagonists. Neurochem. Int., 42, 283, 2003.

3. Glantz S.A., Slinker B.K.: editors (2001). Primer of applied regression and analysis of variance, second edition. McGraw-Hill Inc.: New York, NY.

4. Krauss G.L.: Perampanel: a selective AMPA antagonist for treating seizures. Epilepsy Curr., 13, 269, 2013.

5. Litchfield J.T., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96, 99, 1949.

6. Löscher W., Fassbender C.P., Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res., 8, 79, 1991.

7. Löscher W., Wauquier A.: Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res., Suppl. 11, 61, 1996.

8. Łuszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J.: Isobolographicanalysis of interactions between 1-methyl-1,2,3,4-tetrahydroiso-quinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol., 602, 298, 2009.

9. Łuszczki J.J., Czuczwar S.J.: How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol. Rep., 57, 782, 2005.

10. Łuszczki J.J., Czuczwar S.J.: Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 529, 2007.

11. Łuszczki J.J. et al.: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch. Pharmacol., 373, 169, 2006.

12. Łuszczki J.J. et al.: Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol., 595, 13, 2008.

13. Łuszczki J.J. et al.: Stiripentol in a dose-dependent manner elevates the threshold for maximal electroshock-induced seizures in mice. J. Pre-Clin. Clin. Res., 1, 155, 2007.

14. Pelletier J.C. et al.: Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem., 39, 343, 1996.

15. Rogawski M.A.: AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol. Scand. Suppl., 197, 9, 2013.

16. Rogawski M.A., Donevan S.D.: AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv. Neurol., 79, 947, 1999.

17. Swinyard E.A., Brown W.C., Goodman L.S.: Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther., 106, 319, 1952.

18. Welch N.C. et al.: Traditional AMPA receptor antagonists partially block Na v1.6-mediated persistent current. Neuropharmacology, 55, 1165, 2008.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Copyright (c) 2014 Authors

Downloads

Download data is not yet available.